查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592908

流感治療藥物市場：按藥物類別、給藥方式、流感類型、分銷管道、最終用戶 - 2025-2030 年全球預測

Influenza Medication Market by Drug Class (Baloxavir, Oseltamivir, Peramivir), Delivery Form (Inhalers, Intravenous, Liquid/Syrup), Influenza Type, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年流感治療市值為34.4億美元，預計到2024年將達到36億美元，複合年成長率為5.00%，預計到2030年將達到48.4億美元。

流感治療市場由用於預防、緩解和治療流感症狀的物質定義，包括抗病毒藥物和各種支持性治療。這些藥物的需求源自於流感的季節性流行和潛在的嚴重性，這構成了重大的公共衛生挑戰。應用範圍從個人預防措施到醫療保健組織採用的更廣泛的公共衛生策略。最終用途包括醫院、藥局和網路藥局，滿足處方藥和非處方藥的需求。影響市場成長的主要因素包括全球流感預防意識的提高、藥物配方的進步以及政府擴大健康措施。還有機會擴展到目前進入受限的新興市場，並開發更有效的輸送機制，例如吸入器和速效製劑。然而，來自學名藥的競爭、嚴格的監管條件以及對疫苗的不願意等限制和挑戰可能會限制市場成長。疫苗技術的持續創新，特別是通用流感疫苗和個人化醫療方法的開發，為成長提供了一個有希望的途徑。此外，數位技術的整合，例如人工智慧驅動的流感預測模型，可以增強分銷策略和市場滲透效率。這些創新有可能提供以消費者為中心的解決方案，以滿足不斷變化的健康需求。此外，經濟壓力會影響消費者的購買力，凸顯出具有成本效益的替代方案和取得策略的重要性。儘管市場競爭激烈且由大型製藥公司主導，但對於能夠提供新穎、高效解決方案的新進業者來說也有空間。根據特定人群的需求客製化您的產品並透過教育宣傳活動擴大知名度可以為您帶來競爭優勢。對於尋求發展的公司來說，專注於與醫療保健提供者的合作並利用人工智慧進行市場洞察和預測將為在這個動態的市場環境中導航和繁榮帶來巨大的好處。

主要市場統計
基準年[2023] 34.4億美元
預測年份 [2024] 36億美元
預測年份 [2030] 48.4億美元
複合年成長率（%） 5.00%

市場動態：揭示快速發展的流感藥物市場的關鍵市場洞察

供需的動態交互作用正在改變流感藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 流感疫情在全球不斷擴大
    • 政府針對流感管理的措施和宣傳計劃
    • 對個人化醫療的興趣日益濃厚
  • 市場限制因素
    • 開發新型流感治療藥物的成本上升
  • 市場機會
    • 流感治療藥物的監管核准迅速增加
    • 開發新配方和輸送方法的有利投資
  • 市場挑戰
    • 流感藥物對健康的不良影響

波特五力：駕馭流感藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解流感藥物市場的外部影響

外部宏觀環境因素在塑造流感治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解流感治療藥物市場的競爭狀況

對流感治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

流感治療市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估流感治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了流感治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對流感治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地流感流行率上升
      • 政府關於流感管理的措施和宣傳計劃
      • 個人化醫療方法的成長趨勢
    • 抑制因素
      • 開發新型流感治療藥物的成本高昂
    • 機會
      • 流感治療藥物的監管核准激增
      • 開發新配方和管理方法的有利投資
    • 任務
      • 流感藥物對健康的不良影響
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的流感治療藥物市場

  • 巴洛沙韋
  • 奧司他韋
  • 帕拉米韋
  • 扎那米韋

第7章依給藥方式分類的流感治療藥物市場

  • 吸入器
  • 靜脈
  • 液體/糖漿
  • 錠劑/膠囊

第8章按流感類型分類的流感治療藥物市場

  • A型
  • B型
  • C型
  • D型

第9章流感治療藥物市場：按分銷管道

  • 離線
  • 線上

第 10 章 流感治療藥物市場：依最終使用者分類

  • 門診手術中心
  • 居家照護設施
  • 醫院/診所

第11章 美洲流感藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太流感藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲流感藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Cocrystal Pharma, Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sandoz International GmbH
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-F6513A06BE18

The Influenza Medication Market was valued at USD 3.44 billion in 2023, expected to reach USD 3.60 billion in 2024, and is projected to grow at a CAGR of 5.00%, to USD 4.84 billion by 2030.

The influenza medication market is defined by the substances used to prevent, reduce, or treat flu symptoms, which can include antiviral drugs and various supportive treatments. The necessity of these medications arises from the seasonal prevalence and potential severity of influenza outbreaks, which pose significant public health challenges. The application spans from individual preventive measures to broader public health strategies employed by healthcare institutions. End-use scope includes hospitals, pharmacies, and online drug stores, catering to both prescription and over-the-counter needs. Key factors influencing market growth include increasing global awareness of flu prevention, advancements in drug formulations, and growing governmental health initiatives. Opportunities arise from the potential to expand into emerging markets where access is currently limited, as well as developing more efficient delivery mechanisms like inhalers or faster-acting formulations. However, limitations and challenges such as high competition from generic drugs, stringent regulatory landscapes, and vaccine hesitancy can restrict market growth. Continuous innovation in vaccine technology, particularly in the development of universal influenza vaccines and personalized medicine approaches, offers promising avenues for growth. Additionally, digital technology integration, such as AI-driven flu prediction models, can enhance distribution strategies and market penetration efficiency. These innovations could offer consumer-centric solutions that meet the evolving health needs. Furthermore, economic pressures can affect consumer purchasing power, highlighting the importance of cost-effective alternatives and access strategies. The market is competitive, with large pharmaceutical companies dominating, but there's room for new entrants that can offer novel, efficient solutions. Tailoring products to demographic-specific needs and expanding awareness through education campaigns could provide competitive advantages. For businesses seeking growth, focusing on collaborations with healthcare providers and leveraging AI for market insight and prediction can offer significant benefits in navigating and thriving within this dynamic market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 3.44 billion
Estimated Year [2024] USD 3.60 billion
Forecast Year [2030] USD 4.84 billion
CAGR (%) 5.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Medication Market

The Influenza Medication Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of influenza across the globe
    • Government initiatives and awareness programs for influenza management
    • Growing inclination towards personalized medicine approaches
  • Market Restraints
    • Associated high cost of novel influenza drug development
  • Market Opportunities
    • Surge in influenza drug approvals from regulatory authorities
    • Favorable investments for development of new formulations and delivery methods
  • Market Challenges
    • Adverse health outcomes of influenza medications

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Medication Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Medication Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Medication Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Medication Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Medication Market

A detailed market share analysis in the Influenza Medication Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Medication Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Medication Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Medication Market

A strategic analysis of the Influenza Medication Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Baloxavir, Oseltamivir, Peramivir, and Zanamivir.
  • Based on Delivery Form, market is studied across Inhalers, Intravenous, Liquid/Syrup, and Tablets/Capsules.
  • Based on Influenza Type, market is studied across Type A, Type B, Type C, and Type D.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Facilities, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of influenza across the globe
      • 5.1.1.2. Government initiatives and awareness programs for influenza management
      • 5.1.1.3. Growing inclination towards personalized medicine approaches
    • 5.1.2. Restraints
      • 5.1.2.1. Associated high cost of novel influenza drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in influenza drug approvals from regulatory authorities
      • 5.1.3.2. Favorable investments for development of new formulations and delivery methods
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse health outcomes of influenza medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Influenza Medication Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Baloxavir
  • 6.3. Oseltamivir
  • 6.4. Peramivir
  • 6.5. Zanamivir

7. Influenza Medication Market, by Delivery Form

  • 7.1. Introduction
  • 7.2. Inhalers
  • 7.3. Intravenous
  • 7.4. Liquid/Syrup
  • 7.5. Tablets/Capsules

8. Influenza Medication Market, by Influenza Type

  • 8.1. Introduction
  • 8.2. Type A
  • 8.3. Type B
  • 8.4. Type C
  • 8.5. Type D

9. Influenza Medication Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Influenza Medication Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Homecare Facilities
  • 10.4. Hospitals & Clinics

11. Americas Influenza Medication Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Influenza Medication Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Influenza Medication Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. AstraZeneca PLC
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Cocrystal Pharma, Inc.
  • 7. CSL Limited
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche AG
  • 11. GlaxoSmithKline PLC
  • 12. Lupin Limited
  • 13. Merck & Co., Inc.
  • 14. NATCO Pharma Limited
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Qiagen N.V.
  • 18. Sandoz International GmbH
  • 19. Sanofi SA
  • 20. Shionogi & Co., Ltd.
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Viatris Inc.
  • 25. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
  • FIGURE 2. INFLUENZA MEDICATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFLUENZA MEDICATION MARKET DYNAMICS
  • TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY LIQUID/SYRUP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE D, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023